You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 2
  • 1527 ENB-003, an ETBR antagonist, in combination with pembrolizumab, shows promise in microsatellite stable platinum refractory/resistant ovarian cancer: data from the ENBOLDEN-101 phase 1B study

Alerts

Article menu

Download PDFPDF

Late-Breaking Abstracts
Clinical Trial in Progress
1527 ENB-003, an ETBR antagonist, in combination with pembrolizumab, shows promise in microsatellite stable platinum refractory/resistant ovarian cancer: data from the ENBOLDEN-101 phase 1B study
You need to be signed in to access email alerts. If you have an account log in with your user name and password. If you don't have an account you can just enter your email address in the email box below.
Sign In to Email Alerts with your Email Address